Affiliation:
1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh11451, Saudi Arabia
Abstract
Background:
Linifanib (LFB) is a tyrosine kinase inhibitor with antineoplastic activity.
The existing methods for the analysis of LFB in bulk and dosage forms do not meet the requirements
of quality control (QC) analysis.
Objective:
The present study was devoted to the development of two methods with high throughputs
for determination of LFB. These methods are 96-microwell plate assay with microplate fluorescence
reader (MWP-FR) and high-performance liquid chromatography with fluorescence detection
(HPLC-FD).
Methods:
The MWP-FR assay was carried out in white opaque 96-well assay plates and the native
fluorescence signals of LFB were measured at 360 nm for excitation and 500 nm for emission. In
the HPLC-FD, the chromatographic separation of LFB and quinine sulphate (QS) as internal standard
(IS) was performed on µ-Bondapack CN HPLC column using a mobile phase consisting of
acetonitrile:water (60:40, v/v) pumped at a flow rate of 1 ml/min in an isocratic mode. The fluorescence
detector was set at 350 nm for excitation and 454 nm for emission.
Results:
The linear ranges of the MWP-FR and HPLC-FD were 1-12 µg/well and 10-500 ng/ml, respectively.
The limits of detection were 0.85 µg/well and 8.24 ng/ml for MWP-FR and HPLC-FD,
respectively. Both MWP-FR and HPLC-FL methods were successfully applied for the determination
of LFB in both bulk and tablets.
Conclusion:
Both methods have high analytical throughputs, they are suitable for use in QC laboratories
for analysis of large numbers of LFB samples, and are environmentally friendly as they consume
low volumes of chemicals and solvents.
Funder
Deputyship for Research & Innovation,
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Molecular Medicine,Biochemistry,Biophysics
Reference40 articles.
1. Faguet G.B.; A brief history of cancer: age-old milestones underlying our current knowledge database. Int J Cancer 2015,136(9),2022-2036
2. Glade-Bender J.; Kandel J.J.; Yamashiro D.J.; VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003,3(2),263-276
3. Zhao Y.; Adjei A.A.; Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 2015,20(6),660-673
4. Yu J.; Ustach C.; Kim H.R.; Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003,36(1),49-59
5. Dunn I.F.; Heese O.; Black P.M.; Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 2000,50(1-2),121-137